Hoth Therapeutics (NASDAQ:HOTH) Rating Reiterated by Benchmark

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “speculative buy” rating reaffirmed by analysts at Benchmark in a report issued on Friday, Benzinga reports. They presently have a $3.00 price target on the stock. Benchmark’s target price would suggest a potential upside of 299.47% from the company’s current price.

Several other brokerages also recently commented on HOTH. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Hoth Therapeutics in a research report on Friday, August 16th. EF Hutton Acquisition Co. I raised shares of Hoth Therapeutics to a “strong-buy” rating in a research report on Wednesday, August 21st.

Hoth Therapeutics Price Performance

Shares of Hoth Therapeutics stock opened at $0.75 on Friday. The company has a 50-day moving average of $0.82 and a 200 day moving average of $0.99. The firm has a market cap of $5.18 million, a price-to-earnings ratio of -0.47 and a beta of 0.84. Hoth Therapeutics has a 1 year low of $0.58 and a 1 year high of $1.73.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.15. On average, equities analysts anticipate that Hoth Therapeutics will post -1.18 EPS for the current year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.